Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at KeyCorp

Exagen (NASDAQ:XGN) had its target price lowered by investment analysts at KeyCorp from $15.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s target price points to a potential upside of 215.96% from the stock’s current price.

XGN has been the topic of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of Exagen in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, January 21st. BTIG Research cut their price target on Exagen from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday. TD Cowen reduced their price target on Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, February 24th. Finally, B. Riley Financial reiterated a “buy” rating and issued a $8.00 price objective (down from $18.00) on shares of Exagen in a research note on Friday, January 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.57.

Exagen Trading Down 2.6%

Shares of XGN stock opened at $3.17 on Wednesday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08. The stock has a market capitalization of $71.72 million, a P/E ratio of -3.45 and a beta of 1.88. The company has a 50 day moving average price of $4.24 and a 200 day moving average price of $7.53. Exagen has a fifty-two week low of $2.91 and a fifty-two week high of $12.23.

Exagen (NASDAQ:XGN) last released its earnings results on Tuesday, March 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $16.46 million. Equities research analysts predict that Exagen will post -0.88 EPS for the current fiscal year.

Insider Activity

In other news, CEO John Aballi sold 15,698 shares of Exagen stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a total transaction of $56,826.76. Following the completion of the sale, the chief executive officer directly owned 687,299 shares of the company’s stock, valued at approximately $2,488,022.38. The trade was a 2.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.60% of the company’s stock.

Hedge Funds Weigh In On Exagen

Several large investors have recently bought and sold shares of the business. FourWorld Capital Management LLC purchased a new position in Exagen during the 2nd quarter worth approximately $1,456,000. Citizens Financial Group Inc. RI purchased a new stake in Exagen in the second quarter valued at approximately $472,000. Calamos Advisors LLC acquired a new stake in shares of Exagen in the second quarter valued at approximately $526,000. Corient Private Wealth LLC acquired a new stake in shares of Exagen in the fourth quarter valued at approximately $88,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Exagen during the fourth quarter worth approximately $82,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen News Roundup

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Record revenue, test-volume growth and higher average selling prices reported for FY2025, supporting the company’s recovery narrative and revenue momentum. GlobeNewswire: FY2025 Results
• Positive Sentiment: Management is expanding the sales force and accelerating its product/innovation cadence while setting a FY2026 revenue target of $70M–$73M, which signals investment for growth and commercialization. Seeking Alpha: Revenue Target & Expansion
• Positive Sentiment: BTIG maintained a “buy” rating despite cutting its price target from $10 to $9, a vote of confidence from an analyst that still implies substantial upside from current levels. StreetInsider: BTIG PT Lowered
• Neutral Sentiment: Q4 EPS of ($0.20) matched expectations and revenue of $16.63M slightly beat estimates — results met near-term forecasts but didn’t provide an upside surprise. Zacks: Q4 Results
• Neutral Sentiment: Management discussed strategic investments and commercialization progress on the Q4 call; useful color for modeling, but no new transformational guidance items were provided. Seeking Alpha: Earnings Call Transcript
• Negative Sentiment: FY2026 revenue guidance of $70M–$73M is below the prior Street consensus (~$74M), and the company did not provide EPS guidance — a downside catalyst that often pressures shares when expectations are trimmed. Press Release / Guidance Details
• Negative Sentiment: Short interest rose ~21% in late February to roughly 1.07M shares (~5.4% of shares outstanding), increasing potential downside pressure and the risk of continued volatility. (Internal short‑interest update)

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.